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Available online 27 January 2017Since their introduction around a decade ago, embolic drug-eluting beads (DEBs) have becomeawell-established
treatment option for the locoregional transarterial treatment of hepatic malignancies. Despite this success, the
therapy is seen to be limited by the choice of drug and more effective options are therefore being sought.
These include the small molecule multi-tyrosine kinase inhibitors (MTKi), which exert an anti-angiogenic and
anti-proliferative effect that could be highly beneﬁcial in combating some of the unwanted downstream conse-
quences of embolization. Vandetanib is an MTKi which acts against such targets as vascular endothelial growth
factor receptor (VEGFR) and epithelial growth factor receptor (EGFR) and has demonstrated modest activity
against hepatocellular carcinoma (HCC), albeit with some dose-limiting cardiac toxicity. This makes this com-
pound an interesting candidate for DEB-based locoregional delivery. In this study we describe the preparation
and characterisation of vandetanib DEBs made from DC Bead™ and its radiopaque counterpart, DC Bead LUMI
™. Drug loading was shown to be dependent upon the pH of the drug loading solution, as vandetanib has mul-
tiple sites for protonation,with the bead platform also having a fundamental inﬂuence due to differences in bind-
ing capacities and bead shrinkage effects. Fourier transform infrared (FTIR) spectroscopy and energy dispersive
X-ray (EDX) Spectroscopy conﬁrmed drug interaction is by ionic interaction, and in the case of the radiopaque
DEB, the drug is distributed uniformly inside the bead and contributes slightly to the overall radiopacity by virtue
of a bromine atom on the vandetanib structure. Drug release from both bead platforms is controlled and
sustained, with a slightly slower rate of release from the radiopaque bead due to its more hydrophobic nature.
Vandetanib DEBs therefore have suitable characteristics for intra-arterial delivery and site-speciﬁc sustained re-
lease of drug into liver tumours.
© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Transarterial chemoembolization1. Introduction
The current standard of care for intermediate hepatocellular car-
cinoma (HCC) is transarterial chemoembolization (TACE), an image
guided procedure in which a chemotherapeutic agent is injected
via the hepatic artery into the tumour feeding blood vessels. This is
followed by an embolic material which occludes the vessels, with
the aim of starving the tumour of oxygen and nutrients (Bruix et
al., 2004). TACE may also be performed using drug eluting beads
(DEB): embolic microspheres capable of loading positively charged
drugs and releasing them local to the tumour site via ion exchange,
thus reducing systemic drug exposure (Lewis and Holden, 2011).ODEB, radiopaque drug-eluting
omolecular Sciences, University
.V. This is an open access article undThe drug of choice for loading into DEB is usually doxorubicin, a
cytotoxic agent which intercalates with DNA, interfering with
replication (Gewirtz, 1999). However, it has been shown that
hypoxic conditions can lead to doxorubicin resistance in HCC cells
(Cox and Weinman, 2015). Moreover, tumour hypoxia induced by
embolization therapy leads to upregulation of pro-angiogenic
pathways contributing to the formation of new blood vessels
(Liang et al., 2010; Rhee et al., 2007). Anti-angiogenic strategies are
therefore being considered in combination with DEBs to improve
treatment outcomes.
Several trials combining TACE with oral anti-angiogenic therapy
such as sorafenib, sunitinib or bevacizumab are underway or completed
with some promising results, however there remain toxicity issues as-
sociated with oral use of these agents (Lencioni et al., 2016; Erhardt et
al., 2014). DEBs provide an opportunity for local delivery of these
agents, allowing for high local doses and reduced toxicity compared
with oral treatment. Forster et al. were the ﬁrst to demonstrate that
DEBs could be loaded with a combination of drugs (Forster et al.,er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Selection of MTKis and their mode of action and properties.
Compound Mode of action Propertiesa
Axitinib Potent VEGF inhibitor,
inhibits breast cancer
growth, prevents
neoangiogenesis in 9 L
tumours, activity in
refractory met renal cell
DMSO + DMF soluble
Solubility of over 0.2 μg/mL
in aq media with a pH 1.1–
7.8, pKa 4.8
Bosutinib Active inhibitor of Bcr-Abl,
inhibits tumour cell growth,
angiogenesis, growth factor
expression
DMSO + EtOH soluble,
poorly water soluble
Basic pKas 8.04, 4.80, 3.77
Canertinib diHCl Potent pan-erb B tyrosine
kinase inhibitor, irreversible
TK inhibitor, radiosensitiser
10 mg/mL water solubility,
DMSO ≥5.6 mg/mL, logPc
3.05
Dasatinib SRC and BCR/ABL tyrosine
kinase inhibitor, Lyn & Src
kinase inhibitor
Very poorly water soluble
(0.0128 mg/mL), pKas 3.1,
6.8, logP 1.8
Dovitinib MTKi of FGFR 3, inhibits
tumour growth in xenograft
models of colon cancer
DMSO soluble, poorly EtOH
soluble
Erlotinib HCl Targets EGFRTK, potent
inhibitor of JAK2-V617F.
“Tarcecva” approved for
NSCLC, pancreatic and
others
Slight water and methanol
solubility, pKa 5.42, logP 2.7
Geﬁtinib EGFR TK inhibitor. “Iressa”
approved for NSCLC
Solubility 0.027 mg/mL,
sparingly water soluble at
pH 3, pKas 5.4, 7.2, logP 3.2
Imatinib
methane-sulfonate
Inhibits particular TK
enzymes, used to decrease
bcr-abl TK activity.
Gleevec®, indicated for
chronic myelogenous
leukemia, GI stromal
tumours
DMSO and water soluble,
poorly EtOH soluble, logP 3
Lapatinib
toluene-sulfonate
EGFR and HER2/neu dual TK
inhibitor, potent EGFR
kinase inhibitor, can restore
tamoxifen sensitivity.
“Tykerb®” for advanced met
breast cancer
Poorly water soluble
(0.0223 mg/mL), DMSO
soluble, logP 5.4
Lestaurtinib Potent inhibitor of several
TKs FLT-3, TrkA, clinical
activity in AML pts. with
FLT-3 mutations
Very poorly water soluble
Masitinib Protein TK inhibitor, phase
III in dogs with canine mast
cell tumours
Soluble in DMSO
≥95 mg/mL, water
b1.2 mg/mL
Nilotinib Selective BCR-ABL inhibitor
and of proliferation of
haematopoietic cells in CML
and ALL. TK inhibitor Ph I in
CML “Tasigna®”
Poorly water
(0.00201 mg/mL) and
poorly EtOH soluble, DMSO
soluble, logPc 4.51
Pazopanib Selective multitargeted TK
inhibitor, targets VEGFR,
PDGFR and c-kit
Limited solubility in warm
DMSO, poorly water soluble
(0.0433 mg/mL) logPc 3.59
Sorafenib
toluene-sulfonate
Biaryl urea inhibits ERK
pathway and angiogenesis
by targeting VERGFR-2 and
PDGRF-b. “Nexavar®”
approved renal cell
carcinoma and HCC
Poorly water
(0.00171 mg/mL) and EtOH
soluble, DMSO soluble, logP
3.8
Sunitinib Malate Selective inhibitors of MTKs,
inhibits FLT3-ITD
phosphorylation, CSF-1 rK.
“Sutent®” for renal cell
Water soluble at pH 1.2–
6.8, ﬂuorescent, weak base
pKa 8.95, logP 5.2
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drug such as doxorubicin, but also concomitant delivery of an agent
with a complimentary mode of action such as rapamycin in order to
downregulate expression of Hypoxia Inducible Factor Alpha (HIF-1α)
and consequently induction of angiogenesis. Sakr et al. have more re-
cently described a layer-by-layer process for loading bevacizumab
onto DC Bead™ (Sakr et al., 2016) for controlled locoregional delivery
of amonoclonal antibody that inhibits Vascular Endothelial Growth Fac-
tor-A (VEGF-A), a chemical signal for angiogenesis. It is however, the
small molecule multi-tyrosine kinase inhibitors that have attracted
most interest, given the approval of sorafenib (Nexavar®, Bayer-
Onyx) for the treatment of advanced HCC. Sorafenib drug-eluting pep-
tide nanocomposites (Park et al., 2016) and poly(lactide-co-glycolide)
microspheres (Chen et al., 2014; Chen et al., 2015), both with magnetic
resonance imaging (MRI) capability have been described for intra-arte-
rial delivery to treat HCC. Poly(D,L-lactic acid) microspheres have also
been prepared and loaded with either sorafenib or together with cis-
platin and showed that the drug combination had a faster release rate
(Wang et al., 2015) and was more efﬁcacious in cell assays (Wang et
al., 2016) compared to either drug alone. Lahti et al. described the load-
ing of LC Bead with both sorafenib (Lahti et al., 2015a) and sunitinib
(Lahti et al., 2015b) but both processes were inefﬁcient. Fuchs et al.
have reported on a much more comprehensive appraisal of sunitinib
loading into DC Bead™ (Fuchs et al., 2015), correlation of in vitro release
with in vivo pharmacokinetics (Fuchs et al., 2014) and evaluation of an-
titumor effects in a rabbit VX2 embolization model (Bize et al., 2016).
Whilst these studies show great promise and demonstrate feasibility
for the locoregional delivery of MTKis from DEBs, concerns remain
over the severe toxicity of sunitinib in the liver (Cheng et al., 2013)
and alternative suitable MTKi candidates have been sought.
Table 1 outlines a short selection from a broad list of options that
have been considered for MTKi loading into DEBs, taking into ac-
count drug structure, properties and mode of action. Herein we de-
scribe a feasibility study undertaken with one of these candidates,
vandetanib. Vandetanib is a multi-tyrosine kinase inhibitor (MTKi)
which selectively inhibits vascular endothelial growth factor recep-
tor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and
rearranged during transfection (RET) tyrosine kinase (Morabito et
al., 2009). Common adverse events associated with the oral delivery
of vandetanib include diarrhoea and rash, which can occasionally be
severe. Prolongation of the QT interval (a measure of the time be-
tween the start of the Qwave and the end of the T wave in the heart's
electrical cycle and a marker for the potential of ventricular tachyar-
rhythmias) has also been observed (Tsang et al., 2016). The VEGF and
EGF pathways have both been implicated in the pathogenesis of HCC,
and a phase II trial of vandetanib in advanced unresectable HCC
patients showed a suggestion of improvement in progression free
survival and overall survival (Hsu et al., 2012). There is therefore, a
strong rationale for the locoregional delivery of this drug.
In this study the feasibility of loading vandetanib into DEB was
investigated using both DC Bead™ and the recently approved
radiopaque DEB DC Bead LUMI™ (Biocompatibles UK Ltd., Farnham,
UK). This has resulted in an understanding of the interactions
between vandetanib and the hydrogel network of the microspheres
and the physicochemical characteristics of the resulting
vandetanib-eluting beads in terms of maximum drug loading
capacity, morphology, drug distribution and release.carcinoma
Vandetanib VEGFR-dependent tumour
angiogenesis inhibitor, EGFR
& RET-dependent
proliferation inhibitor.
“Zactima®” for follicular,
medullary, anaplastic,
adv/met papillary thyroid
cancer
DMSO soluble, poorly water
soluble (0.008 mg/mL),
soluble at lower pHs, logPc
5.01
Vatalanib DiHCl Selective inhibitor for Water soluble (10 mg/mL),2. Materials and methods
2.1. Materials
DC Bead™ and DC Bead LUMI™, both of diameter range 70–150 μm,
were provided by Biocompatibles Ltd. (Farnham, UK). Vandetanib base
was provided by Astra Zeneca (Macclesﬁeld, UK, N99% purity).
Table 1 (continued)
Compound Mode of action Propertiesa
VEGFR-1&2 TK+ PDGFR-b,
c-KIT & c-FMS
DMSO soluble (85 mg/mL)
a Information sourced from www.drugbank.ca or individual drug FDA labels.
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As vandetanib exhibits pH dependent solubility, solutions were pre-
pared by ﬁrst dissolving the powdered drug in 0.1 M hydrochloric acid
to 70% of the required volume. The solutionwas then adjusted to the re-
quired pHby dropwise addition of sodiumhydroxide, beforemaking up
to volume with puriﬁed water. By this protocol, solutions at pH 2.1 and
4.4 were prepared at a concentration of 20 mg/mL. Solutions at pH 6.8
were prepared at a concentration of 5 mg/mL due to limits in solubility.
To load beads with vandetanib, the packing solution was removed
from bead vials and vandetanib solution was added. Incubation with
the loading solution was performed at room temperature under agita-
tion for a minimum of 2 h. Depleted loading solution was removed
and the beadswashed 3 times in deionisedwater. To determine loading
efﬁciency, vandetanib concentration in the depleted loading solution
and washings was quantiﬁed by HPLC, using a Hypersil Gold C18 col-
umn (Thermo Scientiﬁc, UK) and PDA detector at a wavelength of
254 nm. Mobile phase was a gradient of 0.1% TFA v/v in puriﬁed water
and 0.1% TFA v/v in methanol; ﬂow rate 1 mL/min.
2.3. Bead morphometry
Bead samples before and after vandetanib loading were examined
using an Olympus BX50 optical microscope with attached Colorview
III camera. The diameter of 200 beads per sample was recorded using
Stream software (Olympus, Southend on Sea, UK). Bead density was de-
termined using a displacement assay described in detail previously
(Duran et al., 2016).
2.4. Elemental mapping using SEM-EDX
DC Bead LUMI™was loaded with the maximum vandetanib dose of
135 mg/mL of sedimented beads. Bead samples were embedded in Tis-
sue-Tek optimum cutting temperature compound (Sakura, Thatcham,
UK) on liquid nitrogen and transferred to−80 °C to ensure thorough
freezing. Samples were sectioned in a cryostat (Leica, Milton Keynes,
UK) in 10 μm thick sections and mounted on SEM stubs with carbon
pads. Samples were coated with 4 nm platinum using a Q150T turbo
molecular-pumped sputter coating system (Quorum, Lewes, UK) prior
to SEM-EDX analysis. SEM imaging was carried out on a Zeiss SIGMA
FEG-SEM (Zeiss, Cambridge, UK) scanning electron microscope
equippedwith anOxford Instruments 80mm2X-Max energy dispersive
X-ray analysis system. The sample was left in the SEM for several mi-
nutes prior to imaging to ensure the small amount of water present in
the section was removed under the high vacuum. Elemental mapping
and spectra were acquired for iodine, bromine, ﬂuorine and sulfur on
unloaded DC Bead LUMI™ and DC Bead LUMI™ loadedwith vandetanib
at maximum capacity.
2.5. Vandetanib-bead interactions using Fourier transform infra-red
microscopy
DC Bead LUMI™ loadedwith different doses of vandetanibwere em-
bedded and sectioned into 10 μm slices as described in Section 2.4.
These were subjected to FTIR microscopy point analysis across a 10–
15 different regions of interest across the samples surface. The spectra
were collated and the position of the S_O stretching frequency around
1040–1050 cm−1 was averaged for each sample. The effect of differingconcentrations of drug loading on the stretching absorption of the sulfo-
nate binding groups on the beads could then be evaluated.
2.6. X-ray micro-computer tomography (μ-CT) analysis for bead
radiopacity
Unloaded LUMI™ and LUMI™ loadedwith vandetanib at concentra-
tions of 30, 60 and 100mg/mLwere uniformly suspended in 1% agarose
solution in nunc tubes. μ-CT 3D scanning was performed to quantify in-
dividual bead radiopacity in Hounsﬁeld units (HU) of each bead in the
sample. μ-CT analysis was performed by Reading Scientiﬁc Services
Ltd., Reading, UK.
2.7. Vandetanib release from beads
DC Bead™ and DC Bead LUMI™ were loaded with 20 mg/mL and
40 mg/mL of vandetanib respectively. The volume of DC Bead™ de-
creased by 50% following loading leading to a ﬁnal dose density of
40 mg/mL. Aliquots of 0.3 mL of beads each containing 12 mg vandeta-
nib were placed in amber jars containing 1 L of pH 7 PBS (Source Biosci-
ence, Nottingham, UK), stirring at 200 rpm. At determined time points,
stirring was stopped to allow beads to settle before removing a 5 mL
sample of PBS for vandetanib quantiﬁcation by HPLC as described in
Section 2.2. 5 mL of fresh PBS was replaced after each timepoint.
2.8. Evaluation of suspension, handling and administration of vandetanib
loaded DC Bead LUMI™
A series of evaluationswere conducted to ensure that loading of van-
detanib into the beads did not adversely affect their handling and deliv-
ery through a microcatheter. DC Bead LUMI™ (70–150 μm)was loaded
with 100 mg/mL of vandetanib as described in Section 2.2, excess load-
ing solution removed and the bead slurry (1 mL) mixed with contrast
agent (9 mL Omnipaque 350®, GE Heathcare, Oslo, Norway). After
transferring into a 20 mL Luer-lok™ syringe (BD Plastipak, Temse, Bel-
gium) a three-way stopcock (Discoﬁx®, B. Braun,Melsungen, Germany)
was attached to the syringe and another syringe attached to enable
transfer between them for suspension. Beads were transferred between
two syringes in injection mixture of Omnipaque 350® and water 20
times. Suspension time was measured by the time it took for 25% of
the solution to be free from beads, i.e. time taken for the top of the
bead suspension to fall to 75% of the internal height of the syringe
(n = 3). The suspension was passed through a 2.4 Fr catheter
(Progreat®, Terumo Corp., Tokyo, Japan) and the beads assessed visual-
ly for any signs of deformation of their shape or presence of fragmenta-
tion using optical microscopy as in Section 2.3.
2.9. Stability of vandetanib loaded DC Bead LUMI™ contrast agent
suspension
When used in hospital, on occasion DEBs are often prepared in the
hospital pharmacy the night before and stored in a refrigerator. Drug
elution from vandetanib loaded DC Bead LUMI™ (70–150 μm)
suspended in contrast agent was therefore investigated by taking ali-
quots of the delivery media supernatant over a period of 24 h and
analysing them using the HPLC method described in Section 2.2 to de-
termine the amount of vandetanib eluted (n=3). The chromatographic
peak was also analysed to determine if there was any drug degradation
during this period.
3. Results
3.1. Vandetanib loading and maximum capacity
At acidic pH, positively charged amines on vandetanib molecules in-
teractwith negatively charged sulfonate groupswithin themicrosphere
Fig. 1.Maximum loading of vandetanib in DC Bead™ and DC Bead LUMI™ at varying pH. A) Amount of drug uptake permL of beads (initial volume), bars representmean± SD, n=5; B)
dose density per mL of beads after adjustment for loading induced bead shrinkage.
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tion shown in Fig. 8, the major vandetanib microspecies, a 2+ charged
form and a 1+ charged form, are predominant at pH 2.1 and pH 6.8 re-
spectively, with a 50:50 proportion of each form at pH 4.4. Vandetanib
solutions were prepared at each of these pHs and added to beads in ex-
cess to assess the effect on maximum loading capacity.
Maximum vandetanib capacity increased with pH (proportion of
1+ form) as expected, with maximum capacity at 30 mg/mL for DC
Bead™ and 135 mg/mL for DC Bead LUMI™ (Fig. 1). Initial analysis of
depleted loading solution fromDCBead™ showed a higher than expect-
ed loading efﬁciency, but with subsequent washes in water the actual
loading dose was found to be lower suggesting that some drug was
weakly associated with the bead surface and able to be removed with
water. This effect was less pronounced with DC Bead LUMI™. Below
maximum capacity, a loading efﬁciency of N99% was achieved after
2 h of incubation with loading solution, suggesting fast adsorption of
vandetanib into beads. When considering the respective chemical com-
positions of both beads, the theoretical maximum loading capacity
based upon the content of sulfonic acid drug binding residues is higher
for both DC Bead™ and DC Bead LUMI™ than the actual experimentally
determined maximum drug binding capacity. For DC Bead, the maxi-
mum amount of drug loaded varies from 81 to 91.2% of the theoretical,
compared to 74.5–80.4% for DC Bead LUMI™, both dependent upon the
pH of the loading solution.Fig. 2. (A) UnloadedDCBead™; (B) vandetanib-loadedDCBead™ (30mg/mL, pH 4.6); (C) unlo
bars 100 μm. (E) DC Bead™ and (F) DC Bead LUMI™ size decrease after vandetanib loading at3.2. Bead morphology, size and density after loading
After loading with vandetanib, beads retained a smooth, spherical
appearance (Fig. 2A–D). Loading DC Bead M1™ at maximum vandeta-
nib capacity caused a signiﬁcant decrease in mean diameter (35%,
p b 0.0001) as well as a narrowing of the size distribution (Fig. 2E).
The size decrease showed a trend with decreasing pH. The size reduc-
tion corresponded with a reduction in settled bead volume of over
60%. The bead density increase from 1.03 ± 0.03 g/cm3 (unloaded) to
1.15 ± 0.09 g/cm3 (loaded at 30 mg/mL), this small increase due to
the decrease in size and contraction of the matrix. In contrast, the
mean diameter of DC Bead LUMI™ loaded at maximum capacity did
not signiﬁcantly decrease at any pH (Fig. 2F), despite a 15% reduction
in the settled bead volume at pH 6.8 only. The density increased only
minimally from 1.29 ± 0.03 g/cm3 (unloaded) to 1.31 ± 0.09 g/cm3
when loaded at 100 mg/mL due to the marginal size change.
3.3. Vandetanib distribution in beads
Scanning electron microscopy showed the sectioned internal struc-
ture of DC Bead LUMI™ to be homogeneous and devoid of any visible
pores (Fig. 3(a)). SEM-EDX analysis was used to detect vandetanib dis-
tribution in sectioned sample loaded at maximum capacity of
135 mg/mL. Bromine was selected as the element of interest for theaded DC Bead LUMI™; (D) vandetanib-loadedDC Bead LUMI™ (100mg/mL, pH 4.6). Scale
differing pHs.
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Bead LUMI™. The sulfur and iodine distributions were also mapped to
gain insight into the bead internal structure. Elemental mapping re-
vealed that bromine was evenly distributed throughout the sectioned
beads (Fig. 3(b)), the bromine peak seen in the EDX spectrum (arrow,
Fig. 3(e)) being absent in the spectrum for control (unloaded) beads
(data not shown). Sulfur and iodine distributions also appeared to be
evenly distributed within the bead structure (Fig. 3(c) and (d))
(Duran et al., 2016). The table insert in Fig. 3(e) shows there is an excel-
lent agreement between the measured weight percent of elements byFig. 3. (a) Scanning electron microscopy image of a sectioned vandetanib-loaded DC Bead LU
mapping distribution image; (d) iodine elemental mapping distribution image; (e) EDX elem
analysis (table inset).EDX compared with the theoretical calculated weight percentage ex-
pected based upon 135 mg/mL loading of vandetanib into DC Bead
LUMI™, the latter which possesses 177 mg/mL iodine (Duran et al.,
2016).
3.4. Evaluation of drug-bead interactions using FTIR microscopy
As the dose of vandetanib loaded into DC Bead LUMI™ was in-
creased, the frequency of the S_O stretch from the sulfonate groups
of the beads was seen to shift steadily to lower wavenumber (Fig. 4).MI™ sample; (b) bromine elemental mapping distribution image; (c) sulfur elemental
ental spectrum showing bromine peak for the vandetanib loaded bead and elemental
Fig. 4. Effect of vandetanib loading dose on the S _O stretching frequency from the
sulfonate groups on the beads (error bars = SEM).
27A. Hagan et al. / European Journal of Pharmaceutical Sciences 101 (2017) 22–30This is indicative of an increasing interaction between drug and bead as
all of the bead binding sites become progressively occupied. Samples
loaded using a target loading of 60 mg/mL at pH 6.8, 4.4 and 2.1 gave
rise to similar S _O stretching frequencies at 1041.6 cm−1,
1040.3 cm−1 and 1040.4 cm−1 respectively.3.5. Radiopacity of vandetanib loaded DC Bead LUMI™
Micro-CT analysis of DC Bead LUMI™ shows it to possess an inherent
radiopacity due to the triiodobenzyl moieties attached to the bead
structure (Duran et al., 2016; Levy et al., 2016; Sharma et al., 2016), giv-
ing rise to a baseline radiopacity of 4454 ± 225 Hounsﬁeld units. The
level of radiopacity is seen to increase linearly with increasing loading
of vandetanib into the beads (Fig. 5) until at a loading of 100 mg/mL
of vandetanib, the radiopacity is seen to have increased by 621 Houns-
ﬁeld Units.Fig. 5. Effect of vandetanib loading into DC Bead LUMI™ on radiopacity of the beads. Bars
representmean of all beads in a single scan of the sample (N6000 beads per sample)± SD.
**** = p b 0.0001 by 1 way ANOVA + Holm-Sidak's multiple comparisons test between
doses.3.6. Vandetanib release from beads
The elution of vandetanib from DC Bead™ and DC Bead LUMI™ into
PBS was analysed using an in vitro USP type II dissolution model, using
0.3 mL aliquots of beads that had been loaded at equivalent dose
densities of 40 mg/mL at pH 4.4 (12 mg per aliquot). Drug release
showed a rapid burst phase in the ﬁrst 2 h, after which it began to
plateau (Fig. 6). The total percentage release of vandetanib over the
test period was higher from DC Bead™ than from DC Bead LUMI™,
achieving on average 85% drug release in 24 h, compared to an average
of 50% from DC Bead LUMI™.
3.7. Evaluation of suspension, handling, delivery and stability of vandetanib
loaded DC Bead LUMI™
When DC Bead LUMI loaded with 100 mg of vandetanib was
suspended in Omnipaque 350® (Section 2.8) the beads formed a uni-
form suspension and showed no signs of bead agglomeration. The
bead suspension did not adhere onto the surface of the vial andwas eas-
ily transferred into a syringe for delivery. The average time in suspen-
sion within the syringe was N6.5 min which is more than sufﬁcient for
practical usage. The bead suspension was delivered through a 2.4 Fr
microcatheter with ease and there was no occurrence of catheter block-
age during bead delivery. The beads remained spherical with no signs of
fragmentation post-delivery.
The amount of vandetanib released from the beads into the contrast
medium15min aftermixingwas 3.3mg,which increased to just 3.5mg
in total after 24 h storage. The drug was seen to be unaltered and
remained within speciﬁcation, N98.0% purity with no single impurity
N0.2%. This shows that a bead suspension could be potentially prepared
in advance and stored overnight without signiﬁcant elution of drug into
the delivery medium and without risk of drug degradation.
4. Discussion
Drug candidates that have been loaded into DC Bead™ have conven-
tionally been water soluble cationic salt forms that allow for diffusion
and ion-exchange into the anionically-charged hydrogel matrix of the
bead (Forster et al., 2010; Guiu et al., 2015; Lewis, 2009; Lewis et al.,
2007; Taylor et al., 2007). MTKis represent a group of small molecules
withwidely differing structures that impact drug solubility, lipophilicity
and ionization potential. Different process strategies may therefore be
required when considering how to load sufﬁcient amounts of these
compounds in an efﬁcient way into the bead matrix, and subsequently
what intermolecular drug-bead interactions will control the release of
the molecule.
The chemical structures of a selection of MTKis considered for com-
biningwith DEBs are presented in Fig. 7. Sorafenib loading into DC Bead
™ has been reported but the low solubility of the drug in aqueousmedia
requires a loading process of several sequential sessions of loading from
low drug concentration solution to achieve sufﬁcient quantities of load-
ed drug (Lahti et al., 2015a). This can be overcome by use of a DMSO
swelling process in which drug dissolved in DMSO can be used to
swell the beads, followed by a precipitation step as the drug swollen
beads are immersed inwater (Forster et al., 2012). This however, leaves
the drug in a microprecipitated form in which its elution is dependent
upon the dissolution of the particulates. The partial ethanol solubility
of sorafenib can be used to produce suitable loading solutions in
ethanol:water mixtures in which the drug can be exchanged into the
bead matrix. Sorafenib however, unlike, many of the other MTKis, has
no protonatable amine group and relies upon strong hydrogen bonding
of the amines on the urea group to interact with carboxylate residues in
at its target site. This may also provide a source of interaction between
drug and bead to ensure controlled release.
Sunitinib on the other hand has a pendant tertiary diethyl substitut-
ed amine that can be protonated to provide a ionic interaction with the
Fig. 6. Vandetanib release from DC Bead™ [●] and DC Bead LUMI™ [■] as A) amount released in mg; B) percentage of available dose. 0.3 mL aliquots of beads containing equivalent of
12 mg vandetanib were stirred in 1 L PBS, pH 7. Mean ± SD, n = 3.
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further enhanced with the addition of a sugar or polyol additive to aid
loading (Fuchs et al., 2015). Vandetanib, erlotinib, geﬁtinib and
dasatinib all share a common secondary amine bridging function at-
tached to a pyrimidine ring, providing additional sites of ionization to
aid in ion-exchange and increase the solubility of these compounds in
water at reduced pH. The positive charge residing on this aromatic por-
tion of themolecule however, can be signiﬁcantly delocalised across the
conjugated ring system, which lessens its capability for charge-charge
interaction (Lewis, 2009).
Based on the theoretical ionization of vandetanib in solution at dif-
ferent pH (Fig. 8) and therefore the relative concentrations of different
vandetanib charge forms, the drug loading maximum capacity should
be inﬂuenced by the pH of the loading solution, which has been con-
ﬁrmed in Fig. 1. For both DC Bead™ and DC Bead LUMI™, there was a
positive relationship between pH of the loading solution and the maxi-
mum amount of vandetanib that could be loaded into the beads. This is
due to the fact that as pH decreases, a greater proportion of vandetanib
molecules in solution have 2 positive charges, and can therefore occupy
2 sulfonate binding sites within the beads, shifting towards a 2:1 bind-
ing ratio. Regardless of the pH, neither bead was able to load the theo-
retical maximum drug loading based upon sulfonic acid group
content, although DC Bead™ was seen to load closer to the theoretical
maximum (91.2%) than DC Bead LUMI™ (80.4%), the latter having a
denser, more hydrophobic gel matrix in which access to all binding
sites may be more restricted.
In DC Bead™, a slight decrease in size range was observed with de-
creasing pH. This is in keeping with previously observed effects ofFig. 7. Structure of a selectiloading the antineoplasticmitoxantrone,whichhas 2 positively charged
sites, and thus exerts an increased shrinking effect on DC Bead™which
is suggested to be an effect of ‘pulling’ the hydrogel network closer to-
gether by interacting with multiple sites (Lewis, 2009). The drug-bead
charge-charge interaction through the sulfonate groups was conﬁrmed
by the shift of the S_O stretching frequency to lower wavenumber
with increasing drug dose, a phenomenon also observed for both doxo-
rubicin and irinotecan binding to DC Bead™ (Lewis and Dreher, 2012;
Namur, 2009). Interestingly, when 60 mg/mL loading was performed
at pH2.1, 4.4 and 6.8, the S_O frequencywas seen not to change signif-
icantly, even though at this dose the DC Bead LUMI™ is only at about
50% binding capacity. At pH 2.1 it is expected that vandetanib would
carry two positive charges and hence capable of interaction with nearly
all binding sites in the beads. The second charge residing on the conju-
gated ring system would not be expected to interact as strongly as that
on the piperidine ring as indicated by the lack of change in the S_O
stretching frequency.
Furthermore, although it could be expected that vandetanib mole-
cules binding to 2 sites may be released more slowly in an elution
model, the release proﬁle of vandetanib from DC Bead LUMI™ did not
vary signiﬁcantly depending on the pH of the loading solution (data
not shown). Possible reasons for this are that the ionic interactions are
not strong enough to be affected in this manner, or perhaps the neutral
pH of the elution medium negates this pH dependent effect as soon as
the ion exchange process begins.
Release of vandetanib fromDCBead LUMI™was incomplete, despite
maximumconcentrations reached in the elution vessel remaining lower
than the theoretical solubility of 0.008 mg/mL (Fig. 6A). The higheron of approved MTKis.
Fig. 8. Ionic interaction of DC Bead™ (L groups are present in DC Bead LUMI™) with vandetanib (top); structure of the ionised forms of vandetanib at different pH (middle); (c) theoretical
proportion of the various forms of vandetanib present with pH (adapted from chemicalize.org).
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limits movement of drug molecules out of the beads. However, by
adjusting the pH of the PBS elution medium to 5, vandetanib release
rate from LUMI™was slightly improvedwith total drug release increas-
ing by 10% to 60% (data not shown). Hypoxic tumours are known to be
acidotic due to production of lactic acid by anaerobic glycolysis. More-
over efﬁcient arterial embolization will impede clearance of lactic acid
from tumoural tissues, contributing to the acidic microenvironment
(Chao et al., 2016), which may somewhat facilitate release in the case
of acidic-soluble drugs. Similarly to doxorubicin (Hecq et al., 2013), van-
detanib binding to DEB has been shown to be fully reversible as the total
dose can be extracted using a solution of potassium chloride and etha-
nol. Using improved elution models with open-loop ﬂow through con-
ditions as described by Swaine et al. may facilitate the modelling of
full extended vandetanib release by preventing saturation of elution
medium and more closely mimicking the in vivo situation (Swaine et
al., 2016).
The addition of the iodinated moiety that renders DC Bead LUMI™
radiopaque increases the solid content of the beads (Duran et al.,
2016) and introduces hydrophobic portions to the bead structure
which may interact with various drugs thereby altering drug loading
and release properties. Increasing loading of vandetanib also leads to a
proportional increase in the radiopacity of the DC Bead LUMI™ (Fig. 4)
which is not attributable to a densiﬁcation of the internal structure as
the mean diameter of the beads are essentially unchanged with drug
loading (Fig. 2F). The existence of a bromine atom on the vandetanibstructure is the likely source of the added radiopacity, which increases
by approximately 25–26 Hounsﬁeld units per mg of radiodense atom
(iodine and bromine) present.
The data presented in this study has conﬁrmed that DC Bead LUMI™
has desirable physicochemical characteristics suitable for use as an anti-
angiogenic DEB. Firstly, maximum vandetanib loading capacity is high,
reaching maximum doses of over 120 mg/mL at pH 6.8 and even
when decreasing pH to maintain vandetanib solubility doses of
100 mg/mL are still feasible. The increased solid content leads to a
higher density of drug binding sites than standard DC Bead™. This in-
creased capacity may compensate for the slower drug release rate. Sec-
ondly, DC Bead LUMI™wasmore resistant to size changes after loading
with vandetanib, compared with DC Bead™which had a signiﬁcant re-
duction in bead size and volume. Although there has been a trend to-
wards using smaller size beads in recent years (Lencioni et al., 2012),
it has been observed that particles of around 40 μmpose a risk of poten-
tially fatal complications resulting from off-target embolisation
(Bonomo et al., 2010; Brown, 2004). The radiopacity of DC Bead LUMI
™may also provide advantages in this respect due to the potential for
intra and post-procedural feedback on bead delivery (Duran et al.,
2016). Finally, loading of the drug did not adversely affect the properties
of the beads in terms of their suspension, handling and delivery in con-
trast agent. When mixed into suspension only a small amount of drug
(3.5 mg) was released into Omnipaque contrast agent and the drug
was shown to be stable in this mixture over the 24 h storage condition
selected for the test. These preliminary evaluations conﬁrm that
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a DEB-TACE procedure.
Recent investigations have been performed using DC Bead™ loaded
with the VEGFR inhibitor sunitinib (Fuchs et al., 2015; Fuchs et al.,
2014), which have shown signiﬁcant effects on endothelial cell prolifer-
ation, apoptosis andmigration, with both sunitinib beads and free suni-
tinib having similar activity in vitro. Sunitinib beads had modest anti-
proliferative effects against a range of cancer cell lines, with lack of di-
rect cytotoxicity due to the mechanism of action of sunitinib being
VEGFR inhibition. As well as inhibiting VEGFR, vandetanib also targets
EGFR and therefore has the potential to also directly impede cancer
cell proliferation and induce apoptosis. In vitro assays have revealed
that vandetanib has a signiﬁcant anti-proliferative effect on endothelial
cells and induces apoptosis in hepatoma cell lines at a concentration of
b10 μmol/L (4.75 μg/ml) (Inoue et al., 2012). The elution studies per-
formed here indicate that the release of vandetanib levels in excess of
this concentration is feasible. In support of this preliminary data we
have recently reported on a safety and pharmacokinetics study of van-
detanib DEB-TACE in healthy swine liver which demonstrated that the
treatmentwaswell tolerated and conﬁrmed the presence of therapeutic
concentrations of vandetanib up to 30 days after administration
(Czuczman et al., 2016).
5. Conclusions
Vandetanib can be efﬁciently loaded and released from DC Bead™
and DC Bead LUMI™ whilst maintaining microsphere integrity and
properties suitable for use as an embolization agent. The inclusion of
vandetanib in a DEB warrants further characterisation in vitro and in
vivo to determine its efﬁcacy in models of HCC.
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